The fact that tobacco ingestion can affect how people feel and think has been known for millennia, placing the plant among those used spiritually, honori?cally, and habitually (Corti 1931; Wilbert 1987). However, the conclusion that nicotine - counted for many of these psychopharmacological effects did not emerge until the nineteenth century (Langley 1905). This was elegantly described by Lewin in 1931 as follows: "The decisive factor in the effects of tobacco, desired or undesired, is nicotine. . . "(Lewin 1998). The use of nicotine as a pharmacological probe to und- stand physiological functioning at the dawn of the twentieth century was a landmark in the birth of modern neuropharmacology (Limbird 2004; Halliwell 2007), and led the pioneering researcher John Langley to conclude that there must exist some "- ceptive substance" to explain the diverse actions of various substances, including nicotine, when applied to muscle tissue (Langley 1905). Research on tobacco and nicotine progressed throughout the twentieth century, but much of this was from a general pharmacological and toxicological rather than a psychopharmacological perspective (Larson et al. 1961). There was some attention to the effects related to addiction, such as euphoria (Johnston 1941), tolerance (Lewin 1931), and withdrawal (Finnegan et al. 1945), but outside of research supported by the tobacco industry, addiction and psychopharmacology were not major foci for research (Slade et al. 1995; Hurt and Robertson 1998; Henning?eld et al. 2006; Henning?eld and Hartel 1999; Larson et al. 1961).

Over the past twelve years, the Centre for Medicines Research has held a series of Workshops on a number of topics related to the drug discovery and development process. The major objective of these Workshops has been to provide an international forum for regula tory, academic and industry representatives to debate together, and suggest solutions to, specific problems. The meeting reported in this volume represents a departure from this approach, in that the par ticipants were drawn largely from the pharmaceutical industry. Senior clinicians, pharmacologists and toxicologists from companies in Europe, the USA and Japan met in May 1994 to discuss a scientific rationale for the conduct of toxicity studies to support the clinical development of new medicines, and to begin to work towards an industry consensus. Achievement of such a consensus is seen as an important step in the process leading towards international harmon isation of the recommendations on the timing of toxicity studies in relation to clinical trials."

Paul H. Axelsen concisely summarizes all the essential medical data concerning the leading antimicrobials used in fighting infectious diseases and clearly illustrates their mechanisms of action. The agents described range from antibacterial and antifungal to antiparasitic and antiviral agents, and include immunomodulators and immunizing agents. For each drug discussed, the book allows rapid access to the essential facts concerning its structure and mechanism of action, the spectrum of its activity, its pharmacokinetics, its adverse effects, and its resistance. This book provides medical students, physicians, and allied health professionals with rapid access to the core principles of antimicrobial pharmacology, and a foundation for decisions about the use of antimicrobials in daily practice.

This treatise had its origins in the authors' strong opinion that the discovery of new drugs, especially of innovative therapeutic agents, really does not happen as a spontaneous sequel to investiga tive research, no matter how penetrating such research may be. Rather, it seemed to us that the discovery of innovative therapeutic agents was a very active process, existing in and of itself, and demanding full attention-it was not simply a passive, dependent by-process of investigative research. And yet, many researchers some close confreres of the authors, others more distant-believed otherwise. We felt that their view reflected unrealistic thinking and that reality probably lay closer to what Beyer" maintained: We are taught to believe that if we can understand a disease it should be easy enough to figure out, say, the molecular configuration of a definitive receptor mechanism somewhere along the line and to design a specific drug . . . . And so we start out to understand the disease but never get around to doing much about therapy. The authors very soon realized that there was essentially no quantitive information available on just where and how innovative therapeutic agents were discovered. There were only anecdotal accounts, and these were able to be selected and presented in ways that could be used to defend any point of view."

During the past several years tremendous advancements have been made in the field of pharmacology and therapeutics. While new therapeutic strategies are coming up, old ones are being improved by modifications, or being replaced with newer ones. The major topics covered in this book include: endothelins, current topics in cardiovascular research, molecular pharmacology, recent developments in cancer research, antioxidants, oxidants and human disease, herbal drugs, developments in neuropharmacology, myelin biology and demyelinating disease, pharmacovigilance, role of cytokines in health and disease, ocular pharmacology, detoxification of xenobiotics-biotransformation and transport, and several other topics of current interest. The aim of this book is to fulfill the needs of the basic and clinical researchers as well as the students, particularly related to areas of current interest in pharmacology and therapeutics.

Cocaine has been a socio-medical problem for centuries. In the United States, the first cocaine epidemic occurred between the 1880s and the 1920s. In the 1960s shortages of heroin as well as government programs to stop the smuggling of marijuana may have stimulated the use of cocaine as a substitute. With the development of crack, cocaine became available at a price that made it accessible to virtually anyone. Today, the long-term effects of crack are just beginning to be felt, especially among children born of users. Treatment of cocaine abuse has traditionally been non-pharmacological, although beginning with the 1980s, various drugs have been used to decrease cocaine craving. This bibliography contains more than 600 references, spanning a century of research and writing. Source publications, all of which are annotated, include books, articles, conference proceedings, dissertations, and government publications. The material is organized within four subject-oriented chapters, and alphabetically within each chapter. Author and subject indexes provide additional access. In addition, Miletich includes appendixes on common names for cocaine, videocassettes about the drug, and a timeline. The work will be of value to researchers as well as social workers, psychologists, and others working in the substance abuse field.

The papers assembled in this collection comprise a majority of the oral presentations as well as several poster presentations given at the 22nd Annual Symposium arranged by the Bastern Pennsylvania Branch of the American Society for MicrobioloS)'. The symposium would not be possible without the generous support of the many sponsors (see sponsor list) or without the concerted effort of a11 the Committee members. This Symposium series has evolved into an annual Bastern Pennsylvania Branch ASM event that attracts participants from a wide geographie area. It should be noted that one of the hallmarks of these symposia involves interaction between the presenters and those in attendance. Several authors have altered their by the participants. Therefore, the manuscript that manuscripts based on comments fo11ows should be viewed as a group effort of both the participants and presenters. J ames Poupard Lori Walsh Bruee Kleger ix CONTENTS 1 Introduction 1: CURRENT METHODS The Evolution of Antimicrobial Susceptibility Testing Methods . . . . . . . . . . . . . . . 3 James A. Poupard, Stephen F. Rittenhouse, and Lori R. Walsh Antimicrobial Susceptibility Tests: Testing Methods and Interpretive Problems. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Patrick R. Murray Clinician Utilization of Rapid Antibiotic Susceptibility Data: A Prospective Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Franklin P. Koontz SESSION 2: CONTEMPORARY ISSUES IN SUSCEPTIBILITY TESTING When We Should Be Testing, How Often and What to Report . . . . . . . . . . . . . . . 35 Raymond C. Bartlett Areas of Recent Emphasis of the National Committee for Clinical Laboratory Standards Subcommittee on Antimicrobial Susceptibility Testing . . . . . . . . . . . . . . . . . . . . . . . 61 James H. Jorgensen Non-Traditional Approaches for Quality Control of Antimicrobial Susceptibility Tests . . . . . . . . . . . . . . . . . . . . . . . . .

This book brings together most up-to-date information on different aspects of brain aging and on the strategies for intervention and therapy of age-related brain disorders. It includes 18 chapters by leading researchers, and each chapter is a comprehensive and critical review of the topic in question, discusses the current scenario and focuses on future perspectives. The target readership is the undergraduate and graduate students in the universities, in medical and nursing colleges, along with the post-graduate researchers and practicing clinicians who would like to know about the latest developments in the field of neurodegenerative disorders and their therapeutic interventions. This book will be of much interest to pharmaceutical, nutrition and healthcare industry for an easy access to accurate and reliable information in the field of aging research and intervention.

Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.

Biotechnology may be defined as the application of scientific and engineering principles to the processing of materials by biological agents to provide goods and services (Bullet al., 1982, p. 21) or as any technique that uses living organisms (or parts of organisms) to make or modify products, to improve plants or animals, or to develop microorganisms for specific use (OTC, 1988). In line with these broad definitions we can consider marine biotechnology as the use of marine organisms or their constituents for useful purposes in a controlled fashion. This series will explore a range of scientific advances in support of marine biotechnology. It will provide information on advances in three categories: (1) basic knowledge, (2) ap plied research and development, and (3) commercial and institutional issues. We hope the presentation of the topics will generate interest and interaction among readers in the academic world, government, and industry. This first volume examines chemical and biological properties of some natural products that are useful or potentially useful in research and in the chemical and pharmaceutical industries. One chapter describes a system for producing such substances on a large scale. Biotechnology incorporates molecular biology in order to go beyond tradi tional biochemical technology such as the production of antibiotic drugs from bacterial cultures in bioreactors. Development of the technology for production of antibiotics in this way resulted from fundamental advances in chemistry, phar macology, microbiology, and biochemical engineering."

Important clinical issues as the outcome of long term treatment with antidepressants, the time of onset of the antidepressant response and the limitations of the antidepressants currently available are covered in this monograph. Leading researchers in the area of clinical and experimental psychopharmacology critically assess the progress in their specialist fields. The mechanisms of action of antidepressants are considered, followed by clinical research into the role of the hypothalamic-pituitary-adrenal axis and the immune system in the biology of depression and in response to treatment. The final chapter deals with the important chemical entities now undergoing development as antidepressants. The purpose of this monograph is not only to inform but also to stimulate research into the biology of depression and the mechanisms behind the action of effective antidepressants. This monograph is of interest to psychiatrists, psychologists, pharmacologists, neuroscientists and endocrinologists.

This book fills the void to provide a comprehensive review of the theoretical knowledge and scope of opioid pharmacotherapy in pain medicine. While the information provided is obtainable in other major texts already in print, the present format style plus the illustrations will make easy reading and fast accessibility of information on opioids available. Information provided is based on clinical practice rather than pure experimental for use in daily practice.

For physicians, surgeons, and scientists working on cardiovascular disorders, Applications of Biotechnology in Cardiovascular Therapeutics serves as an invaluable reference by collecting the essential writings of Dr. Kewal K. Jain on the topics of biotechnology as they relate to cardiovascular disease. This thorough volume includes such subjects as biotechnology and therapeutic delivery to the cardiovascular system, cell-selective targeted drug delivery, cell and gene therapies, including antisense and RNA interference, cutting-edge gene therapy approaches, as well as personalized cardiology as a way of integrating new technologies into the selection of the best possible treatment for an individual patient. Selected references from recent literature are collected for each chapter, and the text is supplemented by a variety of useful tables and figures. Comprehensive and up-to-date, Applications of Biotechnology in Cardiovascular Therapeutics will be tremendously useful for those working in life sciences and the pharmaceutical sciences, and the inclusion of some basics of cardiovascular diseases will greatly benefit nonmedical readers as well.

This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells.

Understanding an individual's genetic makeup is the key to creating personalized drugs with greater efficacy and safety, and pharmacogenomics aims to study the complex genetic basis of inter-patient variability in response to drug therapy. Based upon the success of its first edition, the second edition of Pharmacogenomics: Methods And Protocols aims to continue providing readers with high-quality content on the most innovative and commonly adopted technologies in the field of pharmacogenomics as presented by experts in the field. Broken into several sections, this detailed volume examines techniques for interrogating variation in human genes and genomes, functional assessment of genetic variation, both in vitro and in vivo, as well as tools for translation and implementation of pharmacogenetic markers. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to the respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Comprehensive and thoroughly updated, Pharmacogenomics: Methods And Protocols, Second Edition serves as an essential reference and an invaluable source on the latest information in this field.

Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade. Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission.

This latest addition to the Methods in Molecular Medicine series, Anti- ral Methods and Protocols, is opportune because there is an increasing int- est in discovering compounds that are effective against both chronic and acute viral infections. A number of the methods described in the volume are unp- lished and their inclusion indicates the speed at which this field is moving. This volume is not a review but each chapter contains methods validated by the experts who have spent time in developing the protocols. The hallmark of this series is the comprehensive way in which the me- ods are described, which includes a list of all the reagents needed for each protocol. Of importance is the section on tips and pitfalls that the authors have discovered while developing their protocols. The manual itself is designed to be used by researchers in universities and industry who are familiar with a range of biological techniques but who want to set up quickly a novel assay system. We encourage a dialog between readers and authors, which may also result in useful collaborations.